AVCT Avacta Group

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress

LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from October 17-21, 2025. AVA6000 is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment.

The poster presentation will be based on the most recent data analysis from the Phase 1a trial of FAP-Dox (AVA6000) in patients with Fibroblast Activation Protein (FAP)-positive solid tumors. Avacta completed the Phase 1a enrollment dose escalation portion of the clinical trial in late 2024, with patient enrollment ongoing in multiple dose expansion cohorts of a Phase 1b study.

Abstract details are listed below and available online on the ESMO website.

Avacta will hold an investor event shortly after the ESMO presentation. Further details will be made available nearer the time.

Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Session Title: Developmental Therapeutics

Session Date and Time: 17 October, 19:40 - 20:00

Location: Berlin Auditorium - Hub 27

Abstract Presentation Number: 964P

Speaker: William D. Tap

For further information from Avacta, please contact:

Avacta Group plc

Michael Vinegrad, Group Communications

Director
  
Peel Hunt (Nomad and Joint Broker)

James Steel / Chris Golden



  
Panmure Liberum (Joint Broker)

Emma Earl / Will Goode / Mark Rogers



  
Zeus (Joint Broker)

James Hornigold / George Duxberry

Dominic King
  
ICR Healthcare (Europe/UK media and investors)

Mary-Jane Elliott / Jessica Hodgson /

Stephanie Cuthbert


  
Investor Contact

Renee Leck

THRUST Strategic Communications



  
Media Contact

Carly Scaduto

Carly Scaduto Consulting
  

About Avacta - Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.



EN
30/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avacta Group

 PRESS RELEASE

Avacta to Present New FAP Dox (AVA6000) Data at the European Society f...

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from October 17-21, 2025. AVA6000 is a peptide drug conjugate consisting of doxorubicin conjug...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Small Cap Feast: 02/07/2025

* A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and Closing Price on prior day to Publication. Dish of the day Admissions:   Today, none. Yesterday, Elixirr International (ELIX.L) transferred from the AIM to Main Market. Delistings:     Today, Aquis Exchange (AQX.L) and Kinovo (KINO.L) delisted from AIM. Yesterday, Invinity Energ...

 PRESS RELEASE

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer ...

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company’s clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Boga...

Franc Gregori ... (+3)
  • Franc Gregori
  • Lala Gregorek
  • Philippa Gardner

Avacta: Beneath the tip of the pre|CISION iceberg

Avacta’s appreciation of the scope of its pre|CISION-enabled peptide-drug conjugate platform has been augmented through its Tempus AI collaboration, which has provided insights into indication selection that should enable smarter clinical trial planning. This, coupled to new IP, could also support business development activities. Further data from Avacta’s current pipeline, which has the potential to improve the therapeutic index of many highly potent yet systemically toxic oncology drugs, are a...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Small Cap Feast: 19/06/2025

Dish of the day Admissions:   None Delistings:     Induction Healthcare Group (INHC.L) delisted from AIM.     What’s baking in the oven?  Potential**  Initial Public Offerings: Updated 10th June: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announced that its proposed IPO onto the Main Market, which was expected to occur in late June, will be briefly delayed. A routine thematic compliance insp...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch